Comparison
Argireline vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Research other
CAS no.
616204-22-9
80714-61-0
Molecular weight
888.99 g/mol
813.92 g/mol
Half-life
no data
0.3 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2Met-Glu-His-Phe-Pro-Gly-ProMechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
4
of which in humans
2
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1